Streetbeat News

RHHBY

Roche Holding AG

CEO

Severin Schwan

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

35.88

Mkt cap

236B

Volume

211K

High

36.01

P/E Ratio

19.05

52-wk high

42.43

Low

35.76

Div yield

0.04

52-wk low

29.20

Pfizer and Roche have announced advancements in their weight loss drug programs. Pfizer is moving forward with a once-daily version of its weight loss pill, danuglipron, after discontinuing a twice-daily version due to side effects. Roche also reported promising early-stage results for its oral weight-loss drug, CT-996. Both companies aim to compete with Eli Lilly and Novo Nordisk, who currently dominate the weight loss drug market.

Portfolio Pulse from Upwallstreet

July 17, 2024 | 2:48 pm

Stocks of Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics fell on Wednesday following Roche's announcement of promising Phase 1 trial results for its obesity drug CT-996, which showed superior weight loss results compared to existing treatments.

Portfolio Pulse from Vandana Singh

July 17, 2024 | 2:47 pm

Chip stocks fell due to concerns over potential China restrictions and weak guidance from ASML. Roche reported weight loss data, negatively impacting Eli Lilly and Novo Nordisk.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:33 pm

Roche Holdings AG announced positive topline results from a Phase 1 clinical trial for CT-996, a weight loss and type 2 diabetes drug acquired from Carmot Therapeutics. The drug showed significant weight loss in participants and was well tolerated. This positions Roche to potentially capitalize on the growing obesity treatment market.

Portfolio Pulse from Vandana Singh

July 17, 2024 | 11:28 am

Roche's Genentech has revealed positive Phase I results for its oral GLP-1 receptor agonist CT-996, showing significant weight loss in patients with obesity. The treatment demonstrated a -7.3% weight loss compared to -1.2% in the placebo group, with a favorable safety and tolerability profile.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 5:48 am

Roche's Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy failed to show benefit over Merck's Keytruda in lung cancer patients. The study did not meet its primary endpoints of progression-free survival and overall survival. Roche plans to halt the study and evaluate changes to the ongoing tiragolumab program.

Portfolio Pulse from Vandana Singh

July 05, 2024 | 3:01 pm

Roche's Genentech has halted the SKYSCRAPER-06 trial after the combination of tiragolumab, Tecentriq, and chemotherapy showed reduced efficacy compared to the comparator arm. The trial did not meet the primary endpoints of progression-free survival and overall survival.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2024 | 3:01 pm

Roche's Genentech has received FDA approval for Vabysmo Prefilled Syringe (PFS), the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness. This product is designed to simplify administration and will be available for people living with wet AMD, DME, and RVO.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2024 | 3:00 pm

The FDA has approved Epkinly, co-developed by AbbVie and Genmab, for treating relapsed or refractory follicular lymphoma. This approval is based on promising clinical trial results and marks a significant step in oncology treatment. However, market potential is limited by competition and current application scope.

Portfolio Pulse from Vandana Singh

June 27, 2024 | 5:22 pm

The U.S. Supreme Court has backed 21 pharmaceutical and medical equipment companies, including AstraZeneca, Pfizer, GE Healthcare, Johnson & Johnson, and Roche, in a lawsuit accusing them of funding terrorism in Iraq. The case has been sent back to a lower court for reconsideration.

Portfolio Pulse from Vandana Singh

June 24, 2024 | 7:47 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.